Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1993-10-7
|
pubmed:abstractText |
A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double-blind placebo-controlled study with finasteride (Proscar), a 5 alpha-reductase inhibitor, 5 mg or 10 mg/day, or an identical placebo for 3 months; subsequently, 20 patients received finasteride 5 mg/day in an open extension study. Ten of these patients have now completed 3 years of therapy and have been reevaluated with pressure/flow urodynamics. In finasteride-treated patients dihydrotestosterone (DHT) declined by over 60%, remaining unchanged with placebo. Symptom scores fell in both groups of patients, maximum flow rate values decreased on placebo but improved by a mean of 1.5 ml/s in the 10-mg group and 3.3 ml/s in the 5-mg group. After 1 year of therapy, the reduction in symptom score was well maintained and the flow rate had increased by a mean of 2.7 ml/s; the mean prostate volume was reduced by 14% and prostate-specific antigen (PSA) had declined by 28%. In the 10 patients treated for 3 years who consented to further urodynamic study, the maximum urinary flow rate had improved from a mean baseline value of 8.7 ml/s to a mean of 13.8 ml/s, while maximum subtracted voiding pressure had decreased from a mean baseline value of 72 cm H2O to an unobstructed mean value of 44 cm H2O. Side effects were minimal and reversible on stopping the medication.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/5-alpha Reductase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Androstenes,
http://linkedlifedata.com/resource/pubmed/chemical/Azasteroids,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrotestosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Finasteride,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0302-2838
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
20-6
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:7689971-5-alpha Reductase Inhibitors,
pubmed-meshheading:7689971-Aged,
pubmed-meshheading:7689971-Aged, 80 and over,
pubmed-meshheading:7689971-Androstenes,
pubmed-meshheading:7689971-Azasteroids,
pubmed-meshheading:7689971-Dihydrotestosterone,
pubmed-meshheading:7689971-Dose-Response Relationship, Drug,
pubmed-meshheading:7689971-Double-Blind Method,
pubmed-meshheading:7689971-Finasteride,
pubmed-meshheading:7689971-Humans,
pubmed-meshheading:7689971-Male,
pubmed-meshheading:7689971-Middle Aged,
pubmed-meshheading:7689971-Pilot Projects,
pubmed-meshheading:7689971-Prostate-Specific Antigen,
pubmed-meshheading:7689971-Prostatic Hyperplasia,
pubmed-meshheading:7689971-Time Factors,
pubmed-meshheading:7689971-Urodynamics
|
pubmed:year |
1993
|
pubmed:articleTitle |
Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
|
pubmed:affiliation |
Department of Urology and Diagnostic Radiology, St. Bartholomew's Hospital, London, UK.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|